EICHOR
● Active Not Recruiting
Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer
Condition: Colorectal Cancer · Sponsor: Exelixis
About this study
The primary purpose of this study is to evaluate XL092 + atezolizumab versus regorafenib in participants with microsatellite stable/microsatellite instability low (MSS/MSI-low) metastatic colorectal cancer (mCRC) who have progressed during, after or are intolerant to standard-of-care (SOC) therapy.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (133)
| Exelixis Clinical Site #65 | Jonesboro, Alabama, United States | — |
| Exelixis Clinical Site #30 | Phoenix, Arizona, United States | — |
| Exelixis Clinical Site #70 | Tucson, Arizona, United States | — |
| Exelixis Clinical Site #9 | Duarte, California, United States | — |
| Exelixis Clinical Site #55 | La Jolla, California, United States | — |
| Exelixis Clinical Site #77 | Los Angeles, California, United States | — |
| Exelixis Clinical Site #105 | Orange, California, United States | — |
| Exelixis Clinical Site #80 | Santa Monica, California, United States | — |
| Exelixis Clinical Site #5 | Santa Rosa, California, United States | — |
| Exelixis Clinical Site #82 | Sylmar, California, United States | — |
| Exelixis Clinical Site #58 | Torrance, California, United States | — |
| Exelixis Clinical Site #81 | Whittier, California, United States | — |
+ 121 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.